Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165824 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Oral Edaravone Administered in Subjects With ALS
A Phase 3 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT04165824: Completed Phase 3 study, sponsored by Tanabe Pharma America.
NCT04165824 is a Phase 3 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 185 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04165824, a Phase 3 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.
Interventions
- DRUG MT-1186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2021-10-07 |
| Phase | Phase 3 |
What the finished NCT04165824 record still lists
NCT04165824 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which MT-1186 is the first listed.
NCT04165824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04165824 about?
NCT04165824 is a clinical study titled "Safety Study of Oral Edaravone Administered in Subjects With ALS". The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.
What is the current status of trial NCT04165824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2019-11-18. Estimated completion is 2021-10-07.
What interventions are being tested in trial NCT04165824?
The interventions under investigation include: MT-1186 (DRUG).
Who is sponsoring clinical trial NCT04165824?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04165824's enrollment target sits among peer trials
185 1417th of 2000 higher than 583 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI